QS Investors’s Blueprint Medicines BPMC Stock Holding History

QS Investors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$714K	Hold	8,112	–	–	0.01%	601
2021 Q1	$789K	Buy	8,112 +100	+1%	+$9.98K	0.01%	593
2020 Q4	$899K	Sell	8,012 -88	-1%	-$9.27K	0.01%	538
2020 Q3	$751K	Sell	8,100 -29,300	-78%	-$2.26M	0.01%	540
2020 Q2	$2.92M	Hold	37,400	–	–	0.04%	351
2020 Q1	$2.19M	Sell	37,400 -800	-2%	-$51.5K	0.03%	390
2019 Q4	$3.14M	Sell	38,200 -275	-0.7%	-$20.6K	0.03%	431
2019 Q3	$2.83M	Hold	38,475	–	–	0.03%	438
2019 Q2	$3.63M	Sell	38,475 -617	-2%	-$50.9K	0.04%	371
2019 Q1	$3.13M	Sell	39,092 -343	-0.9%	-$25.3K	0.03%	412
2018 Q4	$2.13M	Hold	39,435	–	–	0.03%	529
2018 Q3	$3.08M	Buy	39,435 +38,335	+3,485%	+$2.66M	0.03%	465
2018 Q2	$70K	Hold	1,100	–	–	﹤0.01%	1472
2018 Q1	$101K	Sell	1,100 -1,200	-52%	-$103K	﹤0.01%	1378
2017 Q4	$173K	Buy	+2,300	New	+$162K	﹤0.01%	1258

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

QS Investors's BPMC Position: Q2 2021 in Review

QS Investors held its Blueprint Medicines (BPMC) position steady in Q2 2021 at 8,112 shares worth $714K. The position accounts for 0.01% of the portfolio, ranked #601.

QS Investors first reported a position in BPMC in Q4 2017 and has held it in 15 quarters since. The position peaked at $3.63M in Q2 2019. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

QS Investors held 8,112 shares of Blueprint Medicines worth $714K as of Q2 2021.
QS Investors left its Blueprint Medicines share count unchanged in Q2 2021.
Blueprint Medicines made up 0.01% of QS Investors's portfolio in Q2 2021, its #601 holding.
QS Investors first reported a position in Blueprint Medicines in Q4 2017 and has held it in 15 quarters since.
QS Investors's Blueprint Medicines position peaked at $3.63M in Q2 2019.
281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.